We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues.
- Authors
Holzman, David
- Abstract
The article reports the ambiguities of studies on tamoxifen, antidepressants and CYP2D6. It states that a group of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) impedes with breast cancer drug tamoxifen by preventing the enzyme CYP2D6. Studies at the American Society of Clinical Oncology (ASCO) emphasizes the importance of related research on the effect of CYP2D6 which is a main issue in breast cancer treatment. Question also arises whether SSRIs affect breast cancer recurrence in patients taking tamoxifen.
- Subjects
MEDICAL research; TAMOXIFEN; ANTIDEPRESSANTS; SEROTONIN uptake inhibitors; BREAST cancer treatment
- Publication
JNCI: Journal of the National Cancer Institute, 2009, Vol 101, Issue 20, p1370
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djp366